{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%281+mL+0.9%25+saline+solution%29&page=2",
    "query": {
      "intervention": "Placebo (1 mL 0.9% saline solution)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 215,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%281+mL+0.9%25+saline+solution%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%281+mL+0.9%25+saline+solution%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T02:19:24.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04173819",
      "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 225,
      "start_date": "2019-01-25",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173819"
    },
    {
      "nct_id": "NCT04492475",
      "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 969,
      "start_date": "2020-08-05",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492475"
    },
    {
      "nct_id": "NCT01158729",
      "title": "Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postoperative Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Antithrombin (Recombinant)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Days",
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "4 Days to 30 Days"
      },
      "enrollment_count": 8,
      "start_date": "2011-08",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158729"
    },
    {
      "nct_id": "NCT04603742",
      "title": "Anakinra, COVID-19, Cytokine Storm",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Cytokine Storm",
        "Mechanical Ventilation Complication"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-12",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-25",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603742"
    },
    {
      "nct_id": "NCT04956575",
      "title": "A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Influenza"
      ],
      "interventions": [
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 885,
      "start_date": "2021-07-06",
      "completion_date": "2022-09-27",
      "has_results": true,
      "last_update_posted_date": "2023-10-27",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04956575"
    },
    {
      "nct_id": "NCT04348500",
      "title": "Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2020-04-28",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348500"
    },
    {
      "nct_id": "NCT04508504",
      "title": "PENG Block for Arthroscopic Hip Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postoperative Pain",
        "Hip Arthroscopy"
      ],
      "interventions": [
        {
          "name": "Preop PENG block",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo block",
          "type": "PROCEDURE"
        },
        {
          "name": "Ropivacaine 0.5% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-12-01",
      "completion_date": "2022-02-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04508504"
    },
    {
      "nct_id": "NCT02543268",
      "title": "A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV-Batch #1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 329,
      "start_date": "2015-09-21",
      "completion_date": "2016-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Mishawaka",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543268"
    },
    {
      "nct_id": "NCT04062123",
      "title": "Memory & Conditioning Under Anesthesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anesthesia",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Propofol",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Nerve Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Keith M Vogt",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 92,
      "start_date": "2020-07-30",
      "completion_date": "2024-04-22",
      "has_results": true,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04062123"
    },
    {
      "nct_id": "NCT03219580",
      "title": "The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brow Ptosis",
        "Facial Scarring"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline Flush, 0.9% Injectable Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyelid and Facial Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-05-20",
      "completion_date": "2020-08-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-04T02:19:24.182Z",
      "location_count": 2,
      "location_summary": "Houma, Louisiana • New Orleans, Louisiana",
      "locations": [
        {
          "city": "Houma",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219580"
    }
  ]
}